Co-Authors
This is a "connection" page, showing publications co-authored by Yanfeng Xu and Fengdi Li.
Connection Strength
0.485
-
Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza. Signal Transduct Target Ther. 2021 05 20; 6(1):200.
Score: 0.059
-
Publisher Correction: A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2021 Feb; 590(7844):E23.
Score: 0.058
-
The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro. Biochem Pharmacol. 2021 01; 183:114302.
Score: 0.057
-
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020 10; 586(7830):572-577.
Score: 0.056
-
Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science. 2020 08 14; 369(6505):818-823.
Score: 0.056
-
Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo. Signal Transduct Target Ther. 2020 05 08; 5(1):66.
Score: 0.055
-
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020 07; 583(7818):830-833.
Score: 0.055
-
Age-related rhesus macaque models of COVID-19. Animal Model Exp Med. 2020 Mar; 3(1):93-97.
Score: 0.055
-
An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J Infect Dis. 2014 Jan 15; 209(2):236-42.
Score: 0.035